Protease Assays

Our protease assay panel provides a platform for profiling and screening of new protease inhibitors against all major classes of proteases, such as serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, and metalloproteases. Selective compounds can be further characterized via both biochemical and biophysical platforms, such as surface plasmon resonance for their kinetic profile and mechanism of action.

In the human genome, there are around 500 putative proteases. Proteases play a role in physiological processes by managing complicated proteolytic activities. Many of them have been used as therapeutic targets in the past. However, the specific functions of numerous proteases in various illnesses are uncertain.      

Reaction Biology has developed a protease assay panel for protease screening and profiling to help speed up the drug discovery process for protease inhibitors. Our protease assays are based on the cleavage of fluorogenic peptide substrates for quantification of the proteolytic activity of proteases enabling the screening of direct and allosteric inhibitors.

Proteases are targeted successfully for the treatment of virus infections such as HIV and Hepatitis C. Inhibitors have been approved for the treatment of hypertension (ACE inhibitors), diabetes (DPP-IV inhibitor), and to prevent blood clots (Factor Xa inhibitors). Studies are underway for the treatment of Alzheimer's, COVID-19, and cancer.

Protease panel profiling is a valuable tool to determine the selectivity of a new protease inhibitor and detect off-target effects supporting the creation of save drug candidates. 

• Fluorescence-based and FRET-based protease activity assay
• Low and large-scale protease screening, as well as high-throughput screening options, are available
• Full protease panel protease profiling is performed on a monthly basis
• Discover our new COVID-19-related protease assays here